T-siHER2-NP - PDX Pharmaceuticals
Alternative Names: Nanoparticle loaded with trastuzumab and siRNA - PDX Pharmaceuticals; T-siHER2-NP™Latest Information Update: 25 Aug 2023
At a glance
- Originator PDX Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies; Small interfering RNA
- Mechanism of Action ErbB receptor expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HER2 positive breast cancer
Most Recent Events
- 23 Jun 2023 PDX Pharmaceuticals has patent protection for Pdx-NPTM technology in USA(Company website - PDX Pharmaceuticals)
- 23 Jun 2023 Preclinical trials in HER2-positive-breast-cancer in USA (Parenteral) (PDX Pharmaceuticals pipeline, June 2023)
- 23 Jun 2023 Pharmacodynamics data from preclinical trial in HER2-positive breast cancer released by PDX Pharmaceuticals (PDX Pharmaceuticals pipeline, June 2023)